Mash | List of Frontiers open access articles

Original Research

Accepted on 25 Feb 2026

ATF3 and HNF4A: an oxidative phosphorylation and cholesterol homeostasis-associated diagnostic and therapeutic reproposing framework target for metabolic dysfunction-associated steatohepatitis patients

in Hepatobiliary Diseases

Guiying Zeng
Qi Zhao
Li Jiang
Dongmei Xie
Lin Du
Mei Yang
Mei Luo
Qian Wang

Frontiers in Medicine

132 views

Brief Research Report

Published on 20 Aug 2024

Sexual dimorphism in hepatic PPAR alpha and CYP4a12a expression is associated with reduced development of drug-induced non-alcoholic steatohepatitis in female IL-33−/− mice

in Hepatobiliary Diseases

Chloe Thomas
Dolores B. Njoku

Frontiers in Medicine

doi 10.3389/fmed.2024.1425528

2,993 views
1 citation

Original Research

Published on 16 May 2024

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH

in Inflammation

Sturla Magnus Grøndal
Anna Tutusaus
Loreto Boix
Maria Reig
Magnus Blø
Linn Hodneland
Gro Gausdal
Akil Jackson
Pablo Garcia de Frutos
James Bradley Lorens

Frontiers in Immunology

doi 10.3389/fimmu.2024.1400553

11,127 views
14 citations

Original Research

Published on 04 Nov 2024

Common molecular basis for MASH and hepatitis C revealed via systems biology approach

in Cancer Immunity and Immunotherapy

Yongwei Cheng
Zihao Song
Ye Liu
Xichao Xu
Dali Zhang
Yigui Zou
Liang Liu
Yinzhen Zeng
Wenwen Li
Daming Bai

Frontiers in Oncology

doi 10.3389/fonc.2024.1442221

4,238 views

Original Research

Published on 23 Jan 2026

EMMPRIN deficiency alleviated metabolic-associated steatohepatitis progression via regulation of the UBA52–MCT1 axis

in Gastrointestinal and Hepatic Pharmacology

Linying Lai
Baoyuan Huang
Ziping Song
Xinyan Zhu
Wenzhuo Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1706859

867 views

Original Research

Published on 10 Mar 2026

Impact of pathologically diagnosed metabolic dysfunction-associated steatohepatitis on weight loss outcomes following sleeve gastrectomy

in Hepatobiliary Diseases

Yunmiao Pan
Yunfei Qu
Hanchen Ma
Maoge Wang
Mingwei Zhong
Sanyuan Hu

Frontiers in Medicine

doi 10.3389/fmed.2026.1780788

348 views

Original Research

Published on 21 Oct 2024

Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning

in Inflammation

Chenghui Cao
Wenwu Liu
Xin Guo
Shuwei Weng
Yang Chen
Yonghong Luo
Shuai Wang
Botao Zhu
Yuxuan Liu
Daoquan Peng

Frontiers in Immunology

doi 10.3389/fimmu.2024.1460431

11,683 views
13 citations

Review

Accepted on 08 Apr 2026

The Immunometabolic Nature of MASH: Framing Immune Cells Within Metabolic Dysfunction

in Molecular Innate Immunity

Sergio González-Serrano
Alina-Iuliana Onoiu
Andrea Jiménez-Franco
Vicente Cambra-Cortés
Jordi Camps
Jorge Joven

Frontiers in Immunology

144 views

Original Research

Published on 23 Feb 2021

The Heat Shock Protein 40-Type Chaperone MASH Supports the Endoplasmic Reticulum-Associated Degradation E3 Ubiquitin Ligase MAKIBISHI1 in Medicago truncatula

in Plant Physiology

Marie-Laure Erffelinck
Bianca Ribeiro
Lore Gryffroy
Avanish Rai
Jacob Pollier
Alain Goossens

Frontiers in Plant Science

doi 10.3389/fpls.2021.639625

6,152 views
3 citations

Perspective

Published on 23 Jan 2026

MASH and the race for liver antifibrotics

in Hepatology

Quin Wills

Frontiers in Gastroenterology

doi 10.3389/fgstr.2025.1704078

2,430 views

Original Research

Published on 03 Nov 2025

Multi-omics analysis elucidates the therapeutic mechanisms of the Quzhi formula in metabolic dysfunction-associated steatohepatitis targeting gut microbiota, lipid metabolism, and the role of its metabolite fraxin

in Ethnopharmacology

Jiao-Xiang Wu
Yue-Lan Wu
Mei-Fang Li
Nian Liu
Ying Liu
Yan-Ping Huang
Yuan Gan
Xiao-Yu Wang
Hai-Sheng Chai
Jin Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1694242

1,657 views
1 citation

Original Research

Published on 29 Sep 2025

Coptidis rhizoma ameliorates type 2 diabetes mellitus-related metabolic dysfunction-associated steatohepatitis by downregulating the IL-17RA/NF-κB signaling pathway

in Ethnopharmacology

Ning Yao
Xin Wang
Yajie Chen
Yunjuan Wu
Ying Su
Xinxin Su
Yajuan Geng
Xiaoning Liu
Limin Tian

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1667937

2,272 views

Review

Published on 16 Jul 2024

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases

in Molecular and Cellular Pathology

Reddemma Sandireddy
Suganya Sakthivel
Priyanka Gupta
Jatin Behari
Madhulika Tripathi
Brijesh Kumar Singh

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2024.1433857

76,209 views
149 citations

Original Research

Published on 23 Sep 2024

Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis

in Inflammation

Jung Hoon Cha
Na Ri Park
Sung Woo Cho
Heechul Nam
Hyun Yang
Eun Sun Jung
Jeong Won Jang
Jong Young Choi
Seung Kew Yoon
Pil Soo Sung

Frontiers in Immunology

doi 10.3389/fimmu.2024.1444100

6,419 views
4 citations

Original Research

Published on 20 Apr 2026

Integrated transcriptomic and single cell analysis combined with artificial neural network identifies a robust gene signature for early discrimination of MASL and MASH

in Inflammation

Guo Wu Lin
Zhi Yuan Lin
Qi Yuan Su
Li Ye
Wei Ning Xu
Shun Qiang Nong
Ru Kai Wu
Wei Jie Zhou
Qian Fang Huang

Frontiers in Immunology

doi 10.3389/fimmu.2026.1813173

321 views

Original Research

Published on 15 Apr 2026

Artemisia scoparia extract inhibits oxidative stress and ferroptosis to ameliorate MASH through AGE-RAGE and JAK1-STAT3 signaling

in Ethnopharmacology

Linlin Wang
Yu Miao
Hailong Wang
Hamulati Hasimu
Tengfei Ji
Hua Huang
Guanhua Du
Haji Akber Aisa
Xuelei Xin

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1792221

269 views

Articles

ATF3 and HNF4A: an oxidative phosphorylation and cholesterol homeostasis-associated diagnostic and therapeutic reproposing framework target for metabolic dysfunction-associated steatohepatitis patients

Sexual dimorphism in hepatic PPAR alpha and CYP4a12a expression is associated with reduced development of drug-induced non-alcoholic steatohepatitis in female IL-33−/− mice

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH

Common molecular basis for MASH and hepatitis C revealed via systems biology approach

EMMPRIN deficiency alleviated metabolic-associated steatohepatitis progression via regulation of the UBA52–MCT1 axis

Impact of pathologically diagnosed metabolic dysfunction-associated steatohepatitis on weight loss outcomes following sleeve gastrectomy

Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning

The Immunometabolic Nature of MASH: Framing Immune Cells Within Metabolic Dysfunction

The Heat Shock Protein 40-Type Chaperone MASH Supports the Endoplasmic Reticulum-Associated Degradation E3 Ubiquitin Ligase MAKIBISHI1 in Medicago truncatula

MASH and the race for liver antifibrotics

Multi-omics analysis elucidates the therapeutic mechanisms of the Quzhi formula in metabolic dysfunction-associated steatohepatitis targeting gut microbiota, lipid metabolism, and the role of its metabolite fraxin

Coptidis rhizoma ameliorates type 2 diabetes mellitus-related metabolic dysfunction-associated steatohepatitis by downregulating the IL-17RA/NF-κB signaling pathway

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases

Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis

Integrated transcriptomic and single cell analysis combined with artificial neural network identifies a robust gene signature for early discrimination of MASL and MASH

Artemisia scoparia extract inhibits oxidative stress and ferroptosis to ameliorate MASH through AGE-RAGE and JAK1-STAT3 signaling